A detailed history of Baird Financial Group, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 59,440 shares of ALT stock, worth $382,199. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,440
Holding current value
$382,199
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$6.02 - $9.85 $357,828 - $585,484
59,440 New
59,440 $428,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $315M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Baird Financial Group, Inc. Portfolio

Follow Baird Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.